In the last Investment Centre newsletter for 2021, Money Management looks back at events that shaped markets this year. ...
Synchron advisers and staff can receive a $100 Bunnings gift voucher if they get the COVID-19 vaccine. ...
Drugs are unlikely to be developed as fast as the COVID-19 vaccine, according to American Century fund manager Michael Li, with testing likely to revert back to strict pr...
Despite rumours suggesting otherwise, the Financial Services Council says receiving the COVID-19 vaccine will not invalidate life insurance policies....
The delay to the COVID-19 vaccine roll-out could cost the Government more than $4 billion and increase the likelihood of lockdowns and restrictions....
South East Asian countries that rely on tourism and are experiencing delays in receiving and distributing the COVID-19 vaccine will see a prolonged dip in their markets...
The rollout of the COVID-19 vaccine in Australia has allowed superannuation funds to continue to enjoy the continued market recovery, according to SuperRatings....
COVID-19 may mutate in a way that reduces the effectiveness of current vaccines and this could set back the market’s recovery, according to Magellan. ...
T. Rowe Price believes the speed of Australia’s economic recovery is being underestimated and is less dependent on the success of a vaccine....
There is a very high likelihood of a cyclical recovery and further spread tightening in corporate credit due to stronger global GDP growth, Brandywine Global believes....
In the current volatile environment, failures can lead to permanent losses and dodging losers may be more important than backing winners....
There has been an ‘atypical’ rotation of stocks since the announcement of the COVID-19 vaccine trials with companies with the lowest levels of profitability outperforming...
Stocks that were doing well during the pandemic are unlikely to reverse when a vaccine has been developed as consumers have adjusted to a ‘new normal’....
Platinum International Health Care manager Bianca Ogden is well placed to benefit from the COVID-19 vaccine trials as her fund holds both of the leading players. ...
As Moderna becomes the second firm to announce a successful COVID-19 vaccine trial, its shares have risen by more than 400% since the start of the year. ...
So shareholders lose a dividend plus have seen the erosion of value. Qantas decides to clawback remuneration from Alan ...
This is why I left my last position. There was no interest in giving the client quality time, it was all about bumping ...
So the Hayne Royal Commission has left us with this. What a sad day for the financial planning industry. Clearly most ...